NEURONETICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.49 USD | -0.85% |
|
-8.16% | +20.34% |
| Sales 2024 * | 79.12M 6.6B | Sales 2025 * | 89.41M 7.45B | Capitalization | 105M 8.72B |
|---|---|---|---|---|---|
| Net income 2024 * | -29M -2.42B | Net income 2025 * | -21M -1.75B | EV / Sales 2024 * | 1.32 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.17 x |
| P/E ratio 2024 * |
-3.77
x | P/E ratio 2025 * |
-5.47
x | Employees | 203 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.68% |
More Fundamentals
* Assessed data
More news
Latest transcript on Neuronetics, Inc.
More recommendations
More press releases
| 1 day | -0.85% | ||
| 1 week | -8.16% | ||
| Current month | -26.68% | ||
| 1 month | -26.68% | ||
| 3 months | +4.18% | ||
| 6 months | +232.38% | ||
| Current year | +20.34% |
1 week
3.35
4.17
1 month
3.355.07
Current year
2.415.07
1 year
1.035.07
3 years
1.0317.92
5 years
1.0322.43
10 years
1.0339.39
| Managers | Title | Age | Since |
|---|---|---|---|
Keith Sullivan
CEO | Chief Executive Officer | 66 | 14/20/14 |
Stephen Furlong
DFI | Director of Finance/CFO | 60 | - |
Cory Anderson
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Cascella
CHM | Chairman | 69 | 01/21/01 |
Sheryl Conley
BRD | Director/Board Member | 63 | 01/19/01 |
Wilfred Jaeger
BRD | Director/Board Member | 67 | 01/05/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 3.49 | -0.85% | 44,573 |
| 25/24/25 | 3.52 | -6.13% | 53,002 |
| 24/24/24 | 3.75 | -2.85% | 21,118 |
| 23/24/23 | 3.86 | +3.21% | 41,466 |
| 22/24/22 | 3.74 | -1.58% | 54,966 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
Calendar
07/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.49
USD
Average target price
7
USD
Spread / Average Target
+100.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.34% | 105M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- STIM Stock
